The molecular basis of mouse adaptation by human enterovirus 71 by Chua, B.H. et al.
 
 
MURDOCH RESEARCH REPOSITORY 
 
 
 
 
This is the author’s final version of the work, as accepted for publication  
following peer review but without the publisher’s layout or pagination.  
The definitive version is available at 
http://dx.doi.org/10.1099/vir.0.83676-0   
 
 
 
Chua, B.H., Phuektes, P., Sanders, S.A., Nicholls, P.K. and 
McMinn, P.C. (2008) The molecular basis of mouse adaptation 
by human enterovirus 71. Journal of General Virology, 89 (7). 
pp. 1622-1632. 
 
 
 
 
 
http://researchrepository.murdoch.edu.au/543/ 
 
 
 
 
 
Copyright: © 2008 SGM. 
 
It is posted here for your personal use. No further distribution is permitted. 
 
 
 The molecular basis of mouse adaptation by human enterovirus 71 
Beng Hooi Chua
1,†, Patchara Phuektes
1,
2,†, Sharon A. Sanders
1, Philip K. 
Nicholls
2 and Peter C. McMinn
1,
3 
 
Abstract 
A mouse-adapted strain of human enterovirus 71 (HEV71) was selected by serial passage of a 
HEV71 clinical isolate (HEV71-26M) in Chinese hamster ovary (CHO) cells (CHO-26M) 
and in newborn BALB/c mice (MP-26M). Despite improved growth in CHO cells, CHO-
26M did not show increased virulence in newborn BALB/c mice compared with HEV71-
26M. By contrast, infection of newborn mice with MP-26M resulted in severe disease of high 
mortality. Skeletal muscle was the primary site of replication in mice for both viruses. 
However, MP-26M infection induced severe necrotizing myositis, whereas CHO-26M 
infection caused only mild inflammation. MP-26M was also isolated from whole blood, 
heart, liver, spleen and brain of infected mice. CHO-26M harboured a single mutation within 
the open reading frame (ORF), resulting in an amino acid substitution of K
149→I in the VP2 
capsid protein; two further ORF mutations that resulted in amino acid substitutions were 
identified in MP-26M, located within the VP1 capsid protein (G
145→E) and the 2C protein 
(K
216→R). Infectious cDNA clone-derived mutant virus populations containing the mutations 
identified in CHO-26M and MP-26M were generated in order to study the molecular basis of 
CHO cell and mouse adaptation. The VP2 (K
149→I) change was responsible only for 
improved growth in CHO cells and did not lead to increased virulence in mice. Of the two 
amino acid substitutions identified in MP-26M, the VP1 (G
145→E) mutation alone was 
sufficient to increase virulence in mice to the level observed in MP-26M-infected mice. 
 
The GenBank/EMBL/DDBJ accession numbers for the sequences reported in this paper 
are EU364841 (HEV71-26M), EU376004 (CHO-26M) and EU376005(MP-26M). 
Introduction 
Human enterovirus 71 (HEV71) belongs to the species Human enterovirus A of the 
genus Enterovirus within the family Picornaviridae (Stanway et al., 2005). It is composed of 
a single-stranded, positive-sense RNA of approximately 7500  nt surrounded by an icosahedral 
capsid assembled from 60 copies of each of the four structural proteins, VP1, VP2, VP3 and 
VP4. 
HEV71 was first isolated from an infant with encephalitis in California in 1969 (Schmidt et 
al., 1974) and has since been associated with large outbreaks of hand, foot and mouth disease 
in young children, most recently in the Asia–Pacific region (Chumakov et al., 1979; Lum et 
al., 1998; McMinn et al., 2001a). Although hand, foot and mouth disease is considered a mild 
febrile exanthem of childhood, HEV71 infection is associated with a high prevalence of severe neurological disease, including aseptic meningitis, brainstem and/or cerebellar 
encephalitis and acute flaccid paralysis (reviewed by McMinn, 2002). With the almost 
successful eradication of poliomyelitis, HEV71 is now the leading cause of acute 
neurological infection in children of several Asian countries. Despite this, little is known 
about the pathogenesis of severe disease caused by HEV71. 
Similar to the related poliovirus, HEV71 has a limited host range, with humans the only 
known natural host. Although Old World monkeys such as cynomolgus, rhesus and African 
green monkeys can be infected experimentally with HEV71 (Arita et al., 2005; Chumakov et 
al., 1979; Hashimoto & Hagiwara, 1982;Hashimoto et al., 1978), other animal species, 
including rodents, are resistant to infection. Unfortunately, the high cost of monkeys and their 
maintenance precludes their widespread use for studies of viral pathogenesis. Thus, a small 
animal model would provide a more cost-effective and practical tool for studies of HEV71 
pathogenesis and for vaccine development. 
A recent study has reported the development of a mouse-adapted HEV71 strain (Chen et al., 
2004). Seven-day-old mice infected with mouse-adapted HEV71 by oral, intramuscular 
(i.m.), intraperitoneal (i.p.) or intracerebral (i.c.) inoculation developed acute flaccid paralysis 
mimicking HEV71 infection in humans and monkeys (Chen et al., 2004; Wang et al., 2004). 
Mouse-adapted HEV71 was more virulent in mice, exhibited a larger plaque size and grew 
more rapidly in cell culture than parental virus. Potential virulence determinants of this 
mouse-adapted strain were identified in the 5′-untranslated region (four nucleotide changes), 
the capsid protein VP2 (three nucleotide and one amino acid change) and the non-structural 
protein 2C (eight nucleotide and four amino acid changes) (Wang et al., 2004). However, the 
role of these mutations in the virulence phenotype of the mouse-adapted strain was not 
determined. 
In order to establish a mouse model for studies of HEV71 pathogenesis and for vaccine 
efficacy and immunogenicity testing, we selected a mouse-adapted variant of HEV71 by 
serial passage of a recent clinical isolate. We also report on the molecular mechanism of 
mouse adaptation and virulence of HEV71 in this model. 
Methods 
Cells and viruses. 
African green monkey kidney (Vero) cells (ATCC CCL-81), human rhabdomyosarcoma 
(RD) cells (ATCC CCL-136), simian virus 40-transformed African green monkey kidney 
(COS-7) cells (ATCC CRL-1651) and Chinese hamster ovary (CHO) cells (ATCC CCL-61) 
were maintained in Dulbecco's modified Eagle's medium (DMEM) (MultiCel; Trace 
Biosciences) supplemented with 5 % bovine growth serum (BGS) (MultiSer; Trace 
Biosciences) and 2  mM L-glutamine. HEV71 strain 26M/AUS/4/99 (HEV71-26M) was 
isolated in Western Australia in 1999 (McMinn et al., 2001a). HEV71-26M was plaque 
purified and propagated by six passages in RD cells. To generate mouse-adapted HEV71, 
parental HEV71-26M was first adapted to growth in CHO cells by six passages at an m.o.i. of 
1. CHO-adapted HEV71-26M (CHO-26M) was then passaged six times by i.c. inoculation of 1-day-old BALB/c mice with 10
3 TCID50 virus obtained from clarified brain homogenates. 
Mouse-adapted virus derived from the sixth mouse brain passage was passaged a further two 
times in Vero cells and designated MP-26M. 
RNA extraction, cDNA synthesis and nucleotide sequence analysis. 
RNA was extracted from HEV71-infected cell culture supernatants using a QIAamp viral 
RNA mini kit (Qiagen). First-strand cDNA synthesis was undertaken using SuperScript II 
reverse transcriptase (Invitrogen); viral cDNA was amplified using PCR SuperMix 
(Invitrogen) with gene-specific primers and gel purified using a MinElute gel extraction kit 
(Qiagen). Nucleotide sequences of the whole genome of HEV71-26M, CHO-26M and MP-
26M, infectious cDNA clone-derived virus (CDV) genomic fragments and plasmid DNA 
were determined by automated DNA sequencing using Big Dye Terminator sequencing 
technology. Sequencing was performed at the Australian Genome Research Facility, 
University of Queensland, Australia. Sequence analysis was performed using Chromas 
version 2.3 (Technelysium Pty) and Clone Manager 5/Align Plus 4 software (SciEd Central). 
Construction of full-length infectious cDNA clones of HEV71-26M and variants 
Full-length infectious cDNA clones of HEV71-26M, CHO-26M and MP-26M were 
constructed using RT-PCR, restriction enzyme digestion and cloning, as described below. All 
viral cDNA fragments used for cloning were amplified by PCR using Platinum Taq DNA 
Polymerase High Fidelity (Invitrogen). CompetentEscherichia coli strain XL10-Gold 
(Stratagene) was used for cloning and amplification of all plasmid constructs. Clones were 
screened by restriction enzyme digestion and sequencing. A schematic diagram of the 
infectious cDNA clones prepared in this study is presented in Fig.  1. 
pHEV71-26M. 
The full-length cDNA clone of HEV71-26M was constructed in two subgenomic clones, 
using plasmid pMC18 (Gualano et al., 1998). Plasmid pMC/5′-26M contained nt 1–3114 of 
HEV71-26M, preceded by a SalI restriction site to facilitate cloning, a T7 RNA polymerase 
promoter and two additional 5′ G residues to improve transcription efficiency (Boyer & 
Haenni, 1994). Plasmid pMC/3′-26M contained a SalI restriction site upstream of nt 2809–
7409 of HEV71-26M, a 25mer poly(A) tail and unique MluI and NotI restriction sites 
downstream of the poly(A) tail. pHEV71-26M was then prepared by excising the SalI–
EcoRI
2842fragment from the clone pMC/5′-26M and inserting it into the SalI–EcoRI
2842 site of 
pMC/3′-26M. 
 
 
 
 
  
 
 
Fig. 1.  Schematic representation of the infectious cDNA clones of HEV71-26M, CHO-26M, CHO-26M-VP1m, 
CHO-26M-2Cm and MP-26M. Genome maps of HEV71-26M and its variants are represented as an open box, 
with individual genes and non-coding regions (NCRs) indicated for HEV71-26M. Amino acid mutations 
observed in CHO-26M, CHO-26M-VP1m, CHO-26M-2Cm and MP-26M are shown as open stars. The 
approximate positions of the restriction enzyme sites used in clone construction are indicated on the HEV71-
26M genome. 
 
pCHO-26M. 
The full-length cDNA clone of CHO-26M was constructed by PCR amplification of nt 533–
3111 of CHO-26M containing the VP2 (A
1400→T) mutation. A PCR fragment containing the 
CHO-26M VP2 (A
1400→T) mutation (nt 533–3111) was amplified and digested with HindIII 
and EcoRI, and then subcloned into similarly digested pBR322 to create pBRCHO. 
The HindIII
968–BsiWI
1442 fragment excised from a positive clone (pBRCHO) was then 
introduced into the corresponding region in pHEV71-26M to create pCHO-26M. 
pCHO-26M-VP1m. 
An EcoRI
2842–EcoRV
4819-digested PCR fragment containing the VP1 (G
2876→A) mutation 
was amplified from MP-26M and subcloned into pBR322 to create pBRMP. The EcoRI
2842–
KpnI
3062 fragment from pBRMP was then introduced into the corresponding region of pCHO-
26M to produce pCHO-26M-VP1m. 
pCHO-26M-2Cm. 
Both pBRMP and pCHO-26M were digested with KpnI and EcoRV to introduce aKpnI
3062–
EcoRV
4819 fragment from pBRMP into the corresponding region of pCHO-26M to construct a plasmid containing the MP-26M-associated 2C gene mutation in the CHO-26M 
background. 
pMP-26M. 
The EcoRI
2842–EcoRV
4819 fragment was excised from pBRMP and cloned into the 
corresponding fragment of pCHO-26M to produce a plasmid containing both MP-26M-
associated VP1 and 2C mutations in the CHO-26M background. 
Transfection and recovery of infectious CDV populations. 
Infectious cDNA clones were transfected into COS-7 cells using Lipofectamine 2000 
(Invitrogen). Briefly, COS-7 cells were seeded into 12-well tissue-culture trays (CellStar) at a 
seeding density of 3×10
5 cells per well. After incubation for 18–24  h, cells were washed with 
PBS (pH  7.4) and replaced with serum-free medium (Optimem; Invitrogen) prior to 
transfection. The lipid–nucleic acid complex containing 1.6  μg of each full-length cDNA 
construct, 1.6  μg pCMV-T7Pol expressing the T7 RNA polymerase and 4  μl Lipofectamine 
2000 was added to the cells and incubated for 4  h. The transfection medium was then 
removed and replaced with DMEM supplemented with 2  mM L-glutamine and 2 % BGS and 
the cells incubated for a further 72  h. Transfected cells were subjected to three cycles of 
freeze–thawing and the supernatants clarified by centrifugation at 1000  g for 15  min. CDV 
stocks were passaged once on RD cells and stored at −80  °C until required. CDV stocks are 
designated as such by the prefix CDV to distinguish them from their respective parental 
virus. 
Virus titration and single-step growth kinetics. 
TCID50 assays were performed on Vero cells and virus titres calculated following the method 
of Reed & Muench (1938). Vero cell monolayers (10
4 cells per well) in 96-well tissue-culture 
trays (CellStar) were inoculated with 100  μl 10-fold serial dilutions of each virus stock and 
incubated for 5  days prior to observation of the presence of cytopathic effect. 
RD and CHO cell monolayers grown overnight in 48-well tissue-culture trays (5×10
4 cells 
per well) were infected at an m.o.i. of 5 for 1  h at 37  °C. Inoculated cells were then washed 
three times with PBS and overlaid with 200  μl maintenance medium (DMEM supplemented 
with 2  mM L-glutamine and 2 % BGS) per well. Cells and supernatants were collected every 
4  h for 24  h, with the first time point (time 0) collected immediately after the addition of the 
maintenance medium. Samples at each time point were frozen and thawed three times and 
clarified by centrifugation at 8000  g for 10  min prior to the determination of the virus titre by 
the TCID50 assay. 
Mouse virulence assays. 
Specific-pathogen-free pregnant BALB/c mice were obtained from the Animal Resources 
Centre, Perth, Australia. All experiments were performed on the ensuing litters of newborn 
mice. Mice were housed in filter-topped cages on a deep litter of sawdust and were provided with food and water ad libitum. All mouse studies were approved by the institutional Animal 
Experimentation Ethics Committee. 
In order to minimize distress, 50 % humane end points (HD50) were used instead of 50 % 
lethal end points; HD50 values are calculated from the time of onset of lethal infection (see 
below) instead of waiting until death ensues. Humane end-point assays have been found to be 
almost identical to lethal end-point virulence assays (Wright & Phillpotts, 1998). 
Groups of four to ten 1- or 7-day-old BALB/c mice were infected with serial 10-fold 
dilutions of virus by i.c., i.p. or i.m. inoculation and HD50 values were calculated by the 
method of Reed & Muench (1938). Mean survival time was calculated in groups of ten 7-
day-old BALB/c mice after i.m. inoculation of 10
4TCID50 virus. Infected mice were observed 
twice daily for clinical signs of illness up to 21  days post-infection (p.i.). Mice that developed 
clinical signs of HEV71 infection, including dehydration, lack of feeding, a hunched back, 
paresis and fore- and/or hindlimb paralysis, were sacrificed by an overdose of pentobarbitone 
sodium (100  mg  kg
−1 by i.p. injection). 
Tissue distribution and histological studies. 
Groups of 15 7-day-old BALB/c mice were infected by the i.m. route with 10
4TCID50 virus. 
At the indicated times p.i., three mice from each group were anaesthetized by i.p. injection 
with a mixture of xylazine (20  mg  ml
−1) and ketamine (100  mg  ml
−1) in PBS at 5  μl (g body 
weight)
−1. Whole blood was collected by intracardiac puncture and stored at −80  °C. After 
perfusion with PBS, tissue samples were then collected, weighed individually, snap-frozen in 
liquid nitrogen and stored at −80  °C. Tissues were homogenized with a Dounce homogenizer 
and the homogenates prepared as 10 % (w/v) suspensions in Hanks' balanced salt solution (pH 
8.0). Virus titres in each tissue homogenate were determined by TCID50 assay; titres are 
expressed as TCID50 (ml whole blood)
−1or (g tissue)
−1 (TCID50 ml
−1 or g
−1). 
Tissues for histological analysis were snap-frozen in Tissue-Tek OCT compound (Sakura 
Finetek USA) in liquid nitrogen. Frozen tissue sections (6  μm) were cut on a microtome and 
then mounted onto Superfrost glass slides (VWR Labware), fixed in 10 % formalin (pH  8.0) 
and stained with haematoxylin and eosin. 
Results 
Mouse-adapted HEV71 has increased virulence in newborn mice 
Infection of newborn mice by i.c. inoculation of HEV71-26M does not cause clinically overt 
disease. In order to create a mouse-adapted strain, HEV71-26M was passaged six times 
(m.o.i. of 1) in CHO cells to produce a CHO cell-adapted virus strain (CHO-26M). CHO-
26M was then passaged six times by i.c. inoculation of newborn BALB/c mice 
(10
3 TCID50 virus in 10 % mouse brain suspensions). By the fourth mouse passage, infection 
caused 100 % mortality (data not shown). Virus at the sixth mouse passage was cultured twice 
on Vero cells to generate virus stocks and was designated MP-26M. As both HEV71-26M  
  
 
Fig. 2. Mortality and age-related susceptibility of BALB/c mice infected with HEV71-26M, CHO-26M or MP-
26M. One-day-old BALB/c mice were inoculated by the i.c. (a) or i.p. (b) route with 10-fold serial dilutions of 
HEV71-26M, CHO-26M or MP-26M. ○, 10
1 TCID50MP-26M; •, 10
0 TCID50 MP-26M; ◊, 10
−1 TCID50 MP-
26M; ⧫, 10
−2 TCID50 MP-26M; □, 10
−3 TCID50 MP-26M; ×, 10
1TCID50 CHO-26M; ▵, 10
1TCID50 HEV71-26M. 
(c) BALB/c mice were inoculated by the i.c. route with 10  HD50 MP-26M at the following ages, observed for 21 
days and the percentage survival calculated. ○, 1  day old; •, 3  days old; □, 5  days old; ▪, 7  days old; ▵, 9  days old; 
▴, 14  days old; ◊, 21  days old. and CHO-26M are non-virulent in newborn BALB/c mice (Fig.  2), CHO-26M was selected 
as the parental strain for comparison with MP-26M in mouse virulence assays. 
In order to compare the virulence of MP-26M and CHO-26M, groups of five to ten 1-day-old 
BALB/c mice were inoculated with 10-fold serial dilutions (10
1–10
−3TCID50) of CHO-26M 
or MP-26M by i.c. or i.p. inoculation. MP-26M showed significantly greater virulence in 
newborn BALB/c mice than CHO-26M (Fig.  2). Mice infected with CHO-26M did not 
develop clinical signs of infection at any virus dose. By contrast, all MP-26M-infected mice 
developed fore- and/or hindlimb paralysis, irrespective of the route of inoculation (data not 
shown). Mice succumbed to MP-26M infection between 4 and 9  days after i.c. inoculation 
(Fig.  2a) and between 3 and 8  days after i.p. inoculation (Fig.  2b). HD50 values for MP-26M 
were 5.0×10
−1 TCID50 and 3.2×10
−1 TCID50 after i.c. and i.p. inoculation, respectively. By 
contrast, both HEV71-26M and CHO-26M had HD50values greater than 10
6 TCID50 (data not 
shown). 
Susceptibility of BALB/c mice to infection with mouse-adapted HEV71 
The age dependence of BALB/c mice to infection with MP-26M after i.c. inoculation was 
investigated by infecting groups of four to eight mice at 1, 3, 5, 7, 9, 14 and 21  days of age 
with 10  HD50 (3.2 TCID50) of MP-26M; the results are shown in Fig.  2(c). Mice aged between 
1 and 3  days had a similar mortality profile, with death commencing at 4  days p.i. and 
reaching 100 % mortality by 7  days p.i. Mice aged 5–7  days at infection survived until day 5 
p.i. and reached mortalities of 83.5 and 80.0 %, respectively, by 8  days p.i. All 9-day-old mice 
survived to 6  days p.i. and 60.0 % mortality was observed in this age group at 8  days p.i. Mice 
infected with MP-26M at 14  days of age and older did not develop clinical signs of infection 
and all survived to 21  days p.i. Seven-day-old mice were selected for all subsequent 
experiments. 
In order to determine whether host susceptibility to MP-26M was dependent on virus dose 
and route of inoculation, groups of four to eight 7-day-old mice were inoculated with 10-fold 
serial dilutions of virus by either the i.c., i.p. or i.m. route; the results are shown in Table  1. 
HD50 values of 5×10
2, 3.4×10
3 and 1.5×10
2 TCID50 were calculated after i.c., i.p. and i.m. 
inoculation, respectively. A mortality rate of 100 % was observed at virus doses greater than 
3.4×10
4 TCID50for all three routes of inoculation. At a dose of 3.4×10
3 TCID50, 100 % 
mortality was observed after i.m. inoculation, but only 50.0 and 85.7 % mortality was 
observed after i.p. and i.c. inoculation, respectively. Mortality rates after i.c. and i.m. 
inoculation of 3.4×10
2 TCID50 MP-26M were 42.9 and 25.0 %, respectively; all i.p.-
inoculated mice survived infection with this virus dose. These data indicated that MP-26M 
induces a fatal disease in BALB/c mice in an age-, dose- and route-of-inoculation-dependent 
manner. All MP-26M-infected mice showed similar clinical signs of infection, irrespective of 
the route and dose of inoculation. 
 
 Table 1. Percentage mortality in 7-day-old BALB/c mice after MP-26M infection 
Groups of four to eight mice were inoculated with 10-fold serial dilutions of MP-26M by the i.c. (10  μl), i.p. (50 
μl) or i.m. (5  μl) route and infected mice were observed twice daily for clinical signs of illness up to 14  days p.i. 
 
*HD50 values were determined using the method of Reed & Muench (1938). 
Tissue distribution of CHO-26M and MP-26M in 7-day-old BALB/c mice after i.m. 
inoculation 
In order to investigate differences in tissue tropism between MP-26M and CHO-26M, the 
distribution of both viruses in host tissues was compared after i.m. inoculation. Groups of 7-
day-old BALB/c mice (15 per group) were inoculated by the i.m. route with 
1.5×10
4 TCID50 MP-26M or CHO-26M. Whole blood and tissue samples, including heart, 
liver, spleen, skeletal muscle and brain, were collected at 1, 3, 5 and 7  days p.i. and virus 
titres determined by TCID50 assay (Fig.  3). 
CHO-26M was isolated from the site of inoculation at all times p.i., with the virus titre 
peaking at >10
6 TCID50 g
−1 at 3  days p.i. (Fig.  3a). CHO-26M was also detected at a single 
uninoculated skeletal muscle site of three individual mice at 1, 3 and 5  days p.i. and in the 
brains of two individual mice at 5 and 7  days p.i. (data not shown), indicating that CHO-26M 
is capable of viraemic spread in a proportion of hosts. Despite this, clinically apparent disease 
was not observed in any CHO-26M-infected mice at any time p.i. 
For MP-26M-infected mice, virus was first detected on day 1 in the inoculated left hindlimb 
(mean titre 8.9×10
4 TCID50 g
−1); the virus titre peaked in the left hindlimb at day 3 (mean 
titre 2.8×10
6 TCID50 g
−1) and remained high (>10
6TCID50 g
−1) at 5 and 7  days p.i. (Fig.  3b). 
Viraemia was first detected at 3  days p.i. and was maintained at similar titres 
(∼10
3 TCID50 ml
−1) throughout the experiment. Virus first appeared in heart and spleen and 
in skeletal muscle of the uninoculated limbs at 3  days p.i. and coincided with viraemia, 
suggesting haematogenous spread (Fig.  3b). All MP-26M-infected mice developed flaccid 
limb paralysis by 5  days p.i. Mice that survived to day 7 also developed a hunched posture, 
listlessness and weight loss. Virus titres in uninoculated and inoculated skeletal muscle 
groups were almost identical at 5 and 7  days p.i., indicating that skeletal muscle is the 
primary site of MP-26M replication and the likely source of viraemia. Virus appeared in the 
central nervous system of all MP-26M-infected mice at 5  days p.i., 48  h after the onset of 
viraemia (Fig.  3b). 
 
  
Fig. 3. Growth of CHO-26M and MP-26M in 7-day-old BALB/c mice. Seven-day-old mice were inoculated by 
the i.m. route with 1.5×10
4 TCID50CHO-26M (a) or MP-26M (b). Whole blood and the indicated tissues were 
prepared as 10 % suspensions in Hanks' balanced salt solution (pH  8.0) at the indicated times p.i. and titrated by 
TCID50 assay. Each time point represents the mean tissue titre in at least two mice (TCID50ml
−1 or g
−1). 
Histological analysis of HEV71-infected tissues 
In order to characterize further the pathogenesis of MP-26M and CHO-26M in 7-day-old 
mice, histological changes in the tissues of virus-infected mice were examined. The most 
notable histological changes in CHO-26M-infected mice were identified in skeletal muscle. 
Neutrophil infiltration was observed in the left (inoculated) hindlimb and in the right forelimb 
at 5 and 7  days p.i. (Fig.  4). Mild neutrophil infiltration was also observed in skeletal muscle 
of both right fore- and hindlimbs at 7  days p.i. No obvious abnormalities were observed in the 
heart, liver or spleen of CHO-26M-infected mice at any time p.i. However, solitary 
lymphocytic inflammatory foci were observed in the cervical and lumbar spinal cord sections 
of two CHO-26M-infected mice at 7  days p.i. (Fig.  4). By contrast, intense neutrophil 
infiltration and necrosis of skeletal muscle was observed at the site of inoculation in MP-
26M-infected mice at 3  days p.i. By 5  days p.i., marked neutrophil infiltration was observed in 
all skeletal muscle groups, with necrotizing myositis developing by 7  days p.i. (Fig.  4). In addition, mild neutrophil infiltration was observed in single thoracic and lumbar spinal cord 
sections of two mice at 7  days p.i. (Fig.  4). No obvious histological abnormality was observed 
in heart, liver or spleen tissue at any time after infection, despite the growth of MP-26M in 
these tissues (Fig.  3b). 
 
 
 
 
 
Fig. 4. Histological features of skeletal muscle and spinal cord in 7-day-old BALB/c mice infected by the i.m. 
route with HEV71. Seven-day-old BALB/c mice were infected by the i.m. route with 10
4 TCID50 CHO-26M or 
MP-26M. Three mice were sacrificed on days 1, 3, 5 and 7 p.i. and tissues collected as outlined in Methods. In 
MP-26M-infected tissues (right column), neutrophil infiltration and necrosis of skeletal muscle (arrows) were 
seen at 7  days p.i., and infiltrating neutrophils (arrows) were also observed in thoracic and lumbar spinal cord 
sections of two mice at 7  days p.i. In CHO-26M-infected tissues (middle column), neutrophil infiltration (arrow) 
was seen in skeletal muscle and in cervical and lumbar spinal cord sections (arrows) of two mice at 7  days p.i. 
Mock-infected tissues are shown in the left column. Magnification, ×200. 
 Nucleotide sequence comparison of the genomes of HEV71-26M, CHO-26M and MP-
26M 
The complete nucleotide and deduced amino acid sequences of HEV71-26M, CHO-26M and 
MP-26M were compared in order to identify mutations associated with adaptation of virus to 
growth in CHO cells and in BALB/c mice (Fig.  5c⇓). Comparison of the HEV71-26M and 
CHO-26M sequences revealed four nucleotide differences, all of which were located in the 
virus polyprotein open reading frame (ORF); only one of these mutations resulted in a change 
in the deduced amino acid sequence, in VP2 (K
149→I). Four additional nucleotide sequence 
changes were identified in the ORF of MP-26M, and two of these mutations resulted in 
deduced amino acid changes in VP1 (G
145→E) and 2C (K
216→R). No nucleotide sequence 
changes were observed in the 5′ and 3′ non-coding regions of all three virus populations. 
Furthermore, the two mutations identified in the 2C gene were not located within the 
HEV71 cis-replication element (data not shown). 
 
 
Fig. 5. Growth in cell culture and mutations identified in CDV HEV71-26M and variants. RD and CHO cells 
were inoculated with the indicated virus (m.o.i. of 5 TCID50 per cell) as described in Methods. Tissue-culture 
supernatants were collected at the indicated times and virus titres determined by TCID50 assay; all assays were 
performed in triplicate. Inoculated virus was back-titrated to ensure an m.o.i of 5 TCID50 per cell in each 
experiment. (a) RD cells were inoculated with CDV-HEV71-26M (○), CDV-CHO-26M (•), CDV-CHO-26M-
VP1m (▴), CDV-CHO-26M-2Cm (▵) or CDV-MP-26M (□). (b) CHO cells were inoculated with CDV-HEV71-
26M (○) or CDV-CHO-26M (•). (c) Nucleotide and amino acid changes identified in the genomes of HEV71-
26M, CHO-26M and MP-26M. 
 
 A single amino acid substitution in VP2 (K
149→I) increases the growth of HEV71 in 
CHO cells 
In order to determine whether the VP2 (K
149→I) mutation was responsible for the improved 
growth of virus in cell culture, single-step growth analysis was undertaken in RD and CHO 
cells using CDV populations of HEV71-26M (CDV-HEV71-26M) and CHO-26M (CDV-
CHO-26M). The single-step growth kinetics and virus yields of both viruses were almost 
identical in RD cells (Fig.  5a). By contrast, CDV-CHO-26M replicated more efficiently than 
CDV-HEV71-26M in CHO cells, with maximum titres more than 100-fold higher than that of 
parental virus (Fig.  5b). 
A single amino acid substitution in VP1 (G
145→E) determines the mouse virulence 
phenotype of HEV71 
In order to identify genetic changes associated with the increased virulence observed in 
mouse-adapted virus (MP-26M), 7-day-old BALB/c mice (eight to 12 per group) were 
inoculated by the i.m. route with 10
4 TCID50 of each infectious CDV population (Table  2). As 
expected, the CDV-HEV71-26M and CDV-CHO-26M virus populations caused no 
observable morbidity or mortality in infected mice. By contrast, CDV-MP-26M caused 100 % 
mortality with a mean (±SEM) survival time of 5.0 (±0.0) days p.i. Interestingly, CDV-CHO-
26M-VP1m and CDV-CHO-26M-2Cm had markedly different mouse virulence phenotypes. 
CDV-CHO-26M-2Cm caused no observable signs of infection and no mortality in 7-day-old 
mice. By contrast, CDV-CHO-26M-VP1m caused 100 % morbidity and mortality, with a 
mean survival time of 4.9 (±0.35) days p.i., similar to the parental MP-26M. 
Table 2. 
Percentage mortality and mean survival of 7-day-old BALB/c mice infected by the i.m. route with CDV HEV71 
variants 
 
 
*CDV populations were passaged once in RD cells prior to use in these experiments. 
†Groups of 7-day-old mice (eight to 12 per group) were inoculated by the i.m. route (5  μl) with 10
4 TCID50 of 
each CDV population and observed twice daily for clinical signs of illness up to 14  days p.i.; mean survival time 
(±SEM) is expressed as number of days. 
‡Groups of 7-day-old mice (eight to ten per group) were inoculated by the i.m. route (5  μl) with 10-fold serial 
dilutions (10
0–10
−4TCID50) of each CDV population and observed twice daily for clinical signs of illness up to 
14  days p.i.; HD50 values were determined using the method of Reed & Muench (1938). 
 HD50 values for all CDV HEV71 variants were determined by i.m. inoculation of 7-day-old 
BALB/c mice (eight to ten per group) with serial 10-fold dilutions of virus. Only CDV-MP-
26M and CDV-CHO-26M-VP1m produced measurable HD50values of 5.0 and 1.6 TCID50, 
respectively (Table  2). This result clearly demonstrated that a non-conservative amino acid 
substitution in VP1 (G
145→E) alone was sufficient to confer the mouse virulence phenotype 
observed in both wild-type and clone-derived MP-26M. 
The growth of each of the infectious CDV populations was examined in RD cells. CDV-
HEV71-26M, CDV-CHO-26M and CDV-CHO-26M-2Cm displayed identical single-step 
growth kinetics in RD cells, reaching maximum titres of approximately 10
7.5 TCID50 ml
−1 at 
12  h p.i. (Fig.  5a). The two virus strains containing the VP1 (G
145→E) mutation, CDV-CHO-
26M-VP1m and CDV-MP-26M, grew poorly in RD cells compared with the other viruses, 
with peak titres approximately 100-fold lower than CDV-HEV71-26M, CDV-CHO-26M and 
CDV-CHO-26M-2Cm at 12  h p.i. (Fig.  5a). 
Stability of the MP-26M-associated VP1 (G
2876→A) and 2C (A
4727→G) mutations 
during passage in 7-day-old BALB/c mice and in RD cell culture 
Amino acid substitutions introduced during mouse adaptation may revert to that of the 
parental virus during cell-culture passage (Jia et al., 2001). To determine whether the amino 
acid substitutions observed in VP1 and/or 2C of mouse-adapted virus would revert to the 
wild-type sequence during passage in cell culture, the stability of these mutations was 
determined by examining the VP1 (G
2876→A) and 2C (A
4727→G) nucleotide sequences of 
CDV-MP-26M at increasing passage levels in RD cells. CDV-MP-26M was cultured at an 
m.o.i. of 1 for five passages in RD cells and viral RNA was extracted from culture 
supernatants at approximately 16–18  h p.i. at each passage level. The VP1 and 2C genes were 
amplified by RT-PCR and their nucleotide sequences determined (Table  3). The 2C gene 
mutation was retained during the five passages in RD cells. By contrast, the VP1 gene 
mutation had reverted to the wild-type EV71-26M sequence by the second RD cell passage. 
As the VP1 (G
2876→A) mutation rapidly reverted to the wild-type sequence during passage in 
RD cells, the stability of the mouse-adapted VP1 and 2C mutations was also investigated 
during passage in mice. CDV-MP-26M was passaged five times in 7-day-old BALB/c mice 
by i.m. inoculation (10
4 TCID50). Viral genomic RNA recovered from brain and muscle 
specimens at each passage level was amplified by RT-PCR using primers specific for the 
VP1 and 2C genes and the amplicons were sequenced (Table  3). In contrast to RD cell 
passage, both the VP1 (G
2876→A) and 2C (A
4727→G) mutations persisted for five passages in 
BALB/c mice. 
Discussion 
Similar to all human enteroviruses, HEV71 has a limited host range, with humans the only 
known natural host. Although Old World monkeys such as cynomolgus, rhesus and African 
green monkeys can be infected experimentally with HEV71 (Chumakov et al., 
1979; Hashimoto & Hagiwara, 1982; Hashimoto et al., 1978), other animal species, including 
rodents, are resistant to infection. In a previous study (Chen et al., 2004) as well as in our  Table 3. Stability of the MP-26M-associated VP1 (G
2876→A) and 2C (A
4727→G) nucleotide mutations during 
passage in RD cells and in 7-day-old BALB/c mice 
CDV populations were used in these experiments. 
 
*RD cells were infected with CDV MP-26M at an m.o.i. of 1 for five serial passages. RNA was extracted from 
infected cell-culture supernatants at 18  h p.i., the VP1 and 2C genes were amplified by RT-PCR and the 
amplicons were sequenced. 
†Groups of 7-day-old BALB/c mice were infected by the i.m. route (10
4 TCID50) with CDV MP-26M for five 
serial passages. RNA was extracted from brain and skeletal muscle tissue collected at 5  days p.i., the VP1 and 
2C genes were amplified by RT-PCR and the amplicons were sequenced. 
 
study, a mouse-adapted strain of HEV71 was selected by serial passage of virus in mouse 
brain. However, the molecular mechanism of host-range adaptation by HEV71 has not been 
clarified. 
In order to select a mouse-adapted strain of HEV71, the virus was firstly passaged six times 
in CHO cells. A non-conservative amino acid substitution in the capsid protein VP2 (K
149→I) 
was identified in CHO-adapted virus. Comparison of the single-step growth kinetics of CDV-
HEV71-26M and CDV-CHO-26M in CHO cells clearly demonstrated that the VP2 (K
149→I) 
mutation was responsible for the improved growth of CDV-CHO-26M in this cell 
line. Chen et al. (2004)adapted a clinical isolate of HEV71 (MP-4643) to grow in random-
bred ICR mice. Mice infected by the i.p. route with the mouse-adapted strain died in an age- 
and virus dose-dependent manner. Interestingly, the only capsid protein mutation identified in 
the mouse-adapted virus selected by Chen et al. (2004) was located at the same position in 
VP2, with the positively charged lysine residue substituted by a non-polar leucine residue 
(Wang et al., 2004). Thus, repeated selection at this site in VP2 during mouse (Chen et al., 
2004) or CHO cell (our study) passage suggests that this residue plays an important role in 
the infection cycle of HEV71 in rodent cells. 
The VP2 mutation identified in CHO-26M is located in the EF loop, a major neutralizing 
antigenic site for the related poliovirus (Burke et al., 1991). VP2 forms part of a deep cleft on 
the virion surface of poliovirus that functions as the site of virion attachment to the cellular 
receptor (Hogle et al., 1985). In the related poliovirus, amino acid residues in the EF loop and 
on the inner surface of the N terminus of VP2 have been associated with mouse adaptation 
(Couderc et al., 1994, 1993, 1996). However, the VP2 (K
149→I) mutation identified in CHO-
26M was not sufficient to confer the mouse virulent phenotype, but only conferred improved growth in CHO cells. Studies of virus binding and internalization in CHO cells will help to 
clarify the mechanism by which this mutation confers CHO cell adaptation. 
In our study, only viruses expressing the VP1 (G
145→E) mutation (MP-26M and CHO-26M-
VP1m) were virulent in 7-day-old BALB/c mice, indicating that the VP1 (G
145→E) change is 
a major genetic determinant of mouse adaptation and virulence. Arita et al. (2008) recently 
demonstrated an identical mutation responsible for adaptation of HEV71 to growth in 
SCID/NOD mice. This amino acid substitution was located on the surface-exposed DE loop 
of VP1. Amino acid mutations in the DE loop of the poliovirus VP1 protein display altered 
heat-induced and receptor-mediated capsid conformational changes (Colston & Racaniello, 
1995; Martin et al., 1988, 1991; Wien et al., 1997). Taken together, these data suggest that 
mouse adaptation by HEV71 may involve an early step in virus replication, in particular a 
change in the specificity of receptor binding. It is likely that parental HEV71-26M is unable 
to infect mice due to an inability to bind to or enter mouse cells in order to initiate infection. 
Alternatively, the VP1 G
145→E mutation may allow HEV71 to undergo mouse cell-specific 
post-binding capsid conformational changes or cell penetration. Further investigation is 
needed to understand the mechanism by which this mutation confers mouse adaptation. 
Residue 145 of HEV71 VP1 is highly variable and several residues, including glycine, 
glutamic acid, arginine and alanine, have been identified in field isolates (Cardosa et al., 
2003; McMinn et al., 2001b). Moreover, we could not isolate a CDV population that included 
only the G
145→E mutation due to reversion to the wild-type sequence after a single passage 
in RD cells. This suggests that the CHO-associated VP2 residue I
149 may help to stabilize 
VP1 residue E
145 via an as-yet-unknown interaction between these two capsid proteins. 
Furthermore, the VP2 and VP1 interaction may cooperate to introduce structural change in 
the virion that either allows the recognition of a mouse cell receptor or may facilitate 
receptor-mediated conformational changes after attachment. 
In addition to the VP1 (G
145→E) mutation identified in MP-26M, a second amino acid 
substitution was identified in protein 2C (K
216→R). This mutation was in a different location 
to the four amino acid substitutions identified in the protein 2C of the mouse-adapted strain 
MP-4643 (Chen et al., 2004). Protein 2C functions as a nucleotide triphosphatase and as a 
director of viral replication complexes to cell membranes (Pfister & Wimmer, 
1999; Teterina et al., 2001), and may also play a role in virion assembly (Li & Baltimore, 
1990; Vance et al., 1997). In our study, the 2C (K
216→R) mutation was not responsible for 
the mouse virulence phenotype. Furthermore, no differences in either cell-culture growth 
characteristics or plaque morphology were identified between viruses expressing the wild-
type (lysine) or mutant (arginine) residue at position 216 in 2C (data not shown). Thus, the 
significance of the protein 2C mutation in mouse adaptation remains unclear. 
We have shown that skeletal muscle is the primary site of HEV71 replication in mice. As 
expected, mouse-adapted virus grew more efficiently in skeletal muscle than parental virus, 
yielding approximately 10-fold higher titres. Histological analysis of skeletal muscle showed 
that infection with CHO-26M induced only mild neutrophil infiltration, whereas infection 
with mouse-adapted virus induced marked neutrophil infiltration and severe necrotizing myositis. The presence of necrotizing myositis in MP-26M-infected mice and a lack of 
evidence of central nervous system disease suggests that the flaccid paralysis observed was 
due primarily to myositis. 
In conclusion, we characterized the molecular basis of CHO cell and mouse adaptation by 
HEV71. An amino acid change in VP2 (K
149→I) was solely responsible for adaptation of 
virus to growth in CHO cells. Moreover, an amino acid change in VP1 (G
145→E) was solely 
responsible for mouse adaptation and increased virulence in BALB/c mice. The CHO cell and 
mouse adaptation determinants are likely to be involved in an early event in virus replication, 
such as virus binding and penetration of the cell surface. The identification of viral genomic 
regions responsible for the expanded host range and increased virulence in mice has 
significantly enhanced our understanding of the molecular biology of HEV71. Furthermore, 
knowledge gained from this study will assist in furthering research on virulence of this 
increasingly important human pathogen. 
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